$JAZZ

neutralCLOSED

AI Sentiment Score: 0/100|0 articles (7d)USD

$194.20-3.94 (-1.99%)

Open

$198.14

Day High

$199.92

Day Low

$192.48

Prev Close

$198.14

Volume

900K

Sentiment

0

0B · 0Be

Intraday Price Chart · 5-Min Candles

79 data points · Dashed line = EOD prediction

EOD Prediction

$194.20

+0.00 (+0.00%) vs now

AI Signal

— HOLD

EOD prediction is AI-generated from news sentiment only. Not financial advice.

Latest Analysis for $JAZZ

bullishApr 1, 2026 · 07:30 PM

Healthcare Exposure Focused On Big Pharma? You're Missing Out

The article emphasizes that many investors are heavily focused on large pharmaceutical companies, which may result in overlooked opportunities in the broader healthcare sector. It suggests that smaller biotech firms and innovative healthcare solutions are gaining traction and could provide substantial returns. The shifting market dynamics due to new health technologies and treatments are highlighted. Investors are encouraged to diversify their healthcare portfolio beyond just big pharma stocks to capture these emerging opportunities. Overall, a broader approach to healthcare investments could yield better long-term performance.

Impact Score7/10
bullishMar 12, 2026 · 04:12 PM

Jazz Pharmaceuticals plc (JAZZ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Jazz Pharmaceuticals plc presented at the Barclays 28th Annual Global Healthcare Conference, highlighting their advancements in drug development and promising pipeline of products. The company's focus on innovative therapies and recent financial performance garnered attention from investors. Analysts view the presentation positively, as it reaffirms Jazz's strategic direction and growth potential. Potential partnerships and collaborations discussed could further drive future revenue. Overall, the event reinforced investor confidence in Jazz's market position.

Impact Score8/10
bullishMar 12, 2026 · 03:53 PM

Janus Henderson Global Life Sciences Diversified ADR Managed Account Q4 2025 Commentary

Janus Henderson's Q4 2025 commentary indicates a positive outlook for global life sciences investments. The report highlights trends in biotech and pharmaceuticals that may encourage increased investor confidence. Diversification strategies are emphasized as a means to mitigate volatility in the sector. The commentary also examines macroeconomic factors that could influence life sciences stocks. Overall, the mixed market conditions present both opportunities and risks for investors in this sector.

Impact Score8/10
bearishMar 10, 2026 · 09:02 PM

Israel rejects Lebanon’s request for ‘cessation’ in fighting to allow for talks

Israel has rejected Lebanon's request for a 'cessation' of fighting, indicating ongoing tensions in the region. This development may escalate military activities or lead to further regional instability. A potential meeting in Cyprus suggests some diplomatic efforts, but rejection of the truce implies heightened conflict risks. Investors may see increased volatility in markets sensitive to geopolitical events. Overall, this situation could affect energy prices and security sectors tied to regional dynamics.

Impact Score7/10